Edwards Lifesciences (NYSE:EW)‘s stock had its “buy” rating restated by equities researchers at BMO Capital Markets in a note issued to investors on Friday. They presently have a $137.00 price objective on the medical research company’s stock. BMO Capital Markets’ target price suggests a potential upside of 16.07% from the company’s previous close.

Other analysts have also issued reports about the company. Canaccord Genuity reissued a “buy” rating and set a $137.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, November 29th. SunTrust Banks set a $124.00 price objective on Edwards Lifesciences and gave the stock a “buy” rating in a report on Wednesday, October 25th. Cowen reissued a “buy” rating and set a $135.00 price objective on shares of Edwards Lifesciences in a report on Thursday, October 12th. Royal Bank Of Canada reissued a “buy” rating and set a $130.00 price objective on shares of Edwards Lifesciences in a report on Friday, September 1st. Finally, Barclays decreased their price objective on Edwards Lifesciences from $120.00 to $118.00 and set an “equal weight” rating for the company in a report on Wednesday, October 25th. Seven analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $125.78.

Shares of Edwards Lifesciences (NYSE:EW) opened at $118.03 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.76 and a current ratio of 3.49. The company has a market capitalization of $24,977.51, a P/E ratio of 32.70, a price-to-earnings-growth ratio of 2.11 and a beta of 0.51. Edwards Lifesciences has a twelve month low of $86.55 and a twelve month high of $121.45.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing analysts’ consensus estimates of $0.86 by ($0.02). The company had revenue of $821.50 million for the quarter, compared to the consensus estimate of $833.85 million. Edwards Lifesciences had a return on equity of 27.22% and a net margin of 22.47%. The business’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.68 earnings per share. sell-side analysts predict that Edwards Lifesciences will post 3.76 earnings per share for the current fiscal year.

Edwards Lifesciences declared that its board has approved a stock repurchase plan on Thursday, December 7th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s management believes its shares are undervalued.

In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 32,900 shares of the stock in a transaction on Monday, October 30th. The stock was sold at an average price of $100.93, for a total transaction of $3,320,597.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the stock in a transaction on Friday, September 29th. The stock was sold at an average price of $108.86, for a total value of $576,958.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 139,580 shares of company stock worth $14,849,205. 2.13% of the stock is owned by company insiders.

Several large investors have recently bought and sold shares of EW. Bank of New York Mellon Corp raised its position in shares of Edwards Lifesciences by 161.7% in the second quarter. Bank of New York Mellon Corp now owns 5,304,536 shares of the medical research company’s stock worth $627,207,000 after buying an additional 3,277,726 shares in the last quarter. Koch Industries Inc. raised its position in shares of Edwards Lifesciences by 28,363.1% in the second quarter. Koch Industries Inc. now owns 1,397,254 shares of the medical research company’s stock worth $1,386,000 after buying an additional 1,392,345 shares in the last quarter. Artisan Partners Limited Partnership raised its position in shares of Edwards Lifesciences by 90.6% in the second quarter. Artisan Partners Limited Partnership now owns 1,278,532 shares of the medical research company’s stock worth $151,174,000 after buying an additional 607,784 shares in the last quarter. Janus Henderson Group PLC raised its position in shares of Edwards Lifesciences by 1,135.0% in the third quarter. Janus Henderson Group PLC now owns 619,703 shares of the medical research company’s stock worth $67,739,000 after buying an additional 569,525 shares in the last quarter. Finally, Old Mutual Global Investors UK Ltd. raised its position in shares of Edwards Lifesciences by 83.0% in the third quarter. Old Mutual Global Investors UK Ltd. now owns 1,100,885 shares of the medical research company’s stock worth $120,337,000 after buying an additional 499,436 shares in the last quarter. Hedge funds and other institutional investors own 81.63% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Edwards Lifesciences (EW) Stock Rating Reaffirmed by BMO Capital Markets” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/10/edwards-lifesciences-ew-stock-rating-reaffirmed-by-bmo-capital-markets.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Stock Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related stocks with our FREE daily email newsletter.